A Single Center, Randomized, Double-blind , Single-dose, and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of MW031 and Prolia® in Healthy Adults
Latest Information Update: 22 Mar 2021
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Mabwell (Shanghai) Bioscience
- 22 Mar 2021 New trial record